{"id":30,"date":"2023-07-04T15:08:52","date_gmt":"2023-07-04T14:08:52","guid":{"rendered":"http:\/\/tris.sambrownprojects.com\/?page_id=30"},"modified":"2024-08-14T01:47:58","modified_gmt":"2024-08-14T05:47:58","slug":"pain","status":"publish","type":"page","link":"https:\/\/www.trispharma.com\/innovation\/pain\/","title":{"rendered":"PAIN"},"content":{"rendered":"
[vc_row full_width=”stretch_row” video_bg=”yes” video_bg_url=”\/wp-content\/uploads\/2023\/12\/pain-bg-video_1-lo-res-gradient.mp4″ conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”video-bl-bg” css=”.vc_custom_1723533864780{background-image: url(https:\/\/www.trispharma.com\/wp-content\/uploads\/2024\/08\/pain-bg-video_1-lo-res-gradient.jpg?id=3107) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″ el_class=”col-bl-bg pain-sp-left” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” css=”.vc_custom_1723614476262{padding-left: 50px !important;}”][vc_column_text css=”” el_class=”text-inno text-white txt-pain-sm”]<\/p>\n
[\/vc_column_text][vc_column_text css=”” el_class=”text-white”]Tris Pharma is working with urgency to develop a pipeline of differentiated compounds based on groundbreaking advances in the evolution of pain biology modulation. Our lead investigational compound, cebranopadol, is the world\u2019s first dual nociceptin\/orphanin FQ peptide (NOP) receptor and \u00b5-opioid peptide (MOP) receptor (dual-NMR) agonist,<\/span> and has the potential to offer gold-standard efficacy with minimized risk of detrimental side effects.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” wrap_container=”yes” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”subpage-nav hide-mobile”][vc_column]